Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian Multicenter Study

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 6, 1996, Pages 2089-2097

  Giusti, M ^a,c   Gussoni, G ^b   Cuttica, C M ^a   Giordano, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b IPSEN   (France)

^c DISEM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADOLESCENT; ADULT; ARTICLE; CARBOHYDRATE TOLERANCE; CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE TOLERANCE; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS FUNCTION; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; THYROID HORMONE BLOOD LEVEL;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; GROWTH HORMONE; HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 0029922510     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.6.2089     Document Type: Article

References (48)

1. Van der Lely AJ, Harris AG, Lamberts SWJ. 1992 The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf). 37:181-185.
2. Frohman LS. 1991 Clinical review 22. Therapeutic options in acromegaly. J Clin Endocrinol Metab. 72:1175-1181.
3. Eastman RC, Gordon P, Glatstein E, Roth J. 1992 Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 21:693-712.
4. Wright AD, Hill DM, Lowy C, Fraser TR. 1970 Mortality in acromegaly. Q J Med. 39:1-16.
5. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 12:71-79.
6. Bengtsson B, Eden S, Ernest I, Oden A, Sjogren B. 1988 Epidemiology and long-term survival in acromegaly. Acta Med Scand. 223:327-335.
7. Bates AS, Van't Hoff W, Jones JM, Clayton RN. 1993 An audit of outcome of treatment in acromegaly. Q J Med. 86:293-299.
8. Rajasoorya C, Holdaway IM, Wrightson F, Scott DJ, Iddertson HK. 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41:95-102.
9. Clayton RN. 1993 Editorial: modern management of acromegaly. Q J Med. 86:285-287.
10. Arafah BM, Brodkey JS, Kaufman B, Velasco M, Manni A, Pearson OH. 1980 Transsphenoidal microsurgery in the treatment of acromegaly and gigantism. J Clin Endocrinol Metab. 50:578-585.
11. Serri O, Somma R, Comtois R, et al. 1985 Acromegaly: biochemical assessment of cure after long-term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab. 61:1185-1189.
12. Klibanski A, Zervas NT. 1991 Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med. 324:822-831.
13. Ho KKY, Weissberger AJ. 1994 Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf). 41:75-83.
14. Barreca A, Ciccarelli E, Minuto F, Bruzzi P, Giordano G, Camanni F. 1989 Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol (Copenh), 120:629-635.
15. Levitt NS, Ratanjee BD, Abrahamson MJ. 1995 Do "so-called" normal growth hormone concentrations (2-5 μg/l) indicate cure in acromegaly? Horm Metab Res. 27:185-188.
16. Barkan AL. 1989 Acromegaly. Diagnosis and therapy. Endocrinol Metab Clin North Am. 18:277-310.
17. Sassolas G, Harris AG, James-Deidier A. 1990 Long-term effect of incremental doses of the somatostain analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
18. Ho KY, Weissberger AJ, Marbach P, Lazarus L. 1990 Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreoride) in acromegaly. Ann Intern Med. 112:173-181.
19. Ezzat S, Snyder PJ, Young WF, et al. 1992 Octreoride treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 117:711-718.
20. Morange I, De Boisvilliers F, Chanson P, et al. 1994 Slow-release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 79:145-151.
21. Arosio M, Macchelli S, Rossi CM, Casati G., Biella O, Faglia G. 1995 Effects of treatment with octreotide in acromegalic patients: a multicenter Italian study. Eur J Endocrinol. 133:430-439.
22. Ho KKY, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. 1992 Impact of octreotide, a long-acting somatostatin analogue on glucose tolerance and insulin activity in acromegaly. Clin Endocrinol (Oxf). 36:271-279.
23. Giusti M, Cuttica CM, Cariola G, Valenti S, Sessarego P, Giordano G. 1995 Treatment of acromegaly with octreotide: effectivenes and tolerability of its pulsatile administration by portable pump. Recent Prog Med. 86:189-194.
24. Invitti C, Fatti LM, Cavagnini F, Orskov H, Porcu L, Camboni MG. 1994 Octreotide nasal powder in acromegalic patients: a dose-range and tolerability study. J Endocrinol Invest. 17(Suppl 2):41.
25. Lancranjan I, Bruns C, Grass P, et al. 1995 Sandostatin LAR: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism. 44(Suppl 1):18-26.
26. Heron I, Thomas F, Dero M, et al. 1993 Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analogue BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab. 76:721-727.
27. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. 1994 Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol. 130:229-234.
28. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. 1994 Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol. 131:20-26.
29. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. 1995 Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol. 132:320-325.
30. Montini M, Gianola D, Pagani MD, et al. 1994 Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol (Oxf). 40:401-406.
31. Barreca A, Cariola G, Ponzani P, et al. 1995 Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clin Endocrinol (Oxf). 42:161-167.
32. Reubi JC, Landolt AM. 1989 The growth hormone reponses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 68:844-850.
33. Reisine T, Bell GI. 1995 Molecular biology of somatostatin receptors. Endocr Rev. 16:427-442.
34. Greeman Y, Melmed S. 1994 Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab. 79:724-729.
35. Miller G, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A. 1995 Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 80:1386-1392.
36. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SWJ. 1994 Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology. 134:301-306.
37. Gancel A, Vuillermet P, Lengrand A, Catus F, Thomas F, Kun JM. 1994 Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH secreting pituitary adenomas. Clin Endocrinol (Oxf). 40:421-428.
38. Quabbe H-J, Plöckinger U. 1989 Dose-response study on long-term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab. 68:873-881.
39. Zapf J. 1995 Physiological role of the insulin-like growth binding proteins. Eur J Endocrinol. 132:645-654.
40. Grinspoon S, Clemmons D, Swearingen B, Klibanski A. 1995 Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab. 80:927-932.
41. Ezzat S, Ren SG, Braunstein GD. 1992 Octreotide stimulates insulin-like growth factor-binding protein-I: a potential pituitary independent mechanism for drug action. J Clin Endocrinol Metab. 75:1459-1463.
42. Wolthers T, Grofte T, Flyvbjerg A, et al. 1994 Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog. J Clin Endocrinol Metab. 78:141-144.
43. McKnight JA, McCance DR, Sheridan B, Atkinson AB. 1995 Four years' treatment of resistent acromegaly with octreotide. Eur J Endocrinol. 132:429-432.
44. Kuhn JM, Basin C, Mollard M, De Rouge B, Schatz B, Wolf LM. 1992 Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur J Clin Invest. 22:793-799.
45. Koop BL, Harris AG, Ezzat S. 1994 Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol. 130:581-586.
46. Sassolas G, Khalfallah Y, Chayvialle JA, et al. 1989 Effect of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab. 68:239-246.
47. Chanson P, Warnet A. 1992 Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide. Metabolism. 41:62-65.
48. Fredstorp L, Pernow Y, Werner S. 1993 The short and long-term effects of octreotide on calcium homeostasis in patients with acromegaly. Clin Endocrinol (Oxf). 39:331-336.